dupilumab
R668-ABPA-1923
Phase 2 small_molecule completed
Quick answer
dupilumab for Allergic Bronchopulmonary Aspergillosis is a Phase 2 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- Allergic Bronchopulmonary Aspergillosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed